Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP03
- Development stage
- Unknown
- Lead developer
- Wuhan University
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
CP03: sourced facts only. name: "Among them, CP03 displayed potent and selective ERα degradation and antiproliferative effects in multiple BC cell lines with wild-type or mutant ERα." [PMID:40527751]; target: "Among them, CP03 displayed potent and selective ERα degradation and antiproliferative effects in multiple BC cell lines with wild-type or mutant ERα." [PMID:40527751]; developer: "Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China." [PMID:40527751]; modality: "Herein, we report the development of first-in-class PROTACs targeting the unconventional coactivator binding site (CBS) of ERα." [PMID:40527751]; stage: "In vivo, CP03 exhibited excellent antitumor and ERα degradation activity in MCF-7 and drug-resistant LCC-2 xenografted models." [PMID:40527751]
02
Targets
ESR1 (ERα)
Beyond the preview
Go deeper on CP03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CP03.